Clinical trial • Phase II • Immunology | Rare Disease

IMEROPRUBART for Chronic inflammatory demyelinating polyneuropathy (CIDP)

Phase II trial of IMEROPRUBART for Chronic inflammatory demyelinating polyneuropathy (CIDP).

Overview

Trial Therapeutic Area
Immunology | Rare Disease
Trial Disease
Chronic inflammatory demyelinating polyneuropathy (CIDP)
Trial Stage
Phase II
Drug Modality
Monoclonal antibody

Key dates

Initial CTIS Submission Date
07-07-2025
First CTIS Authorization Date
28-10-2025

Trial design

Randomised, placebo is identical to imp but with no active substance (placebo-controlled). Phase II trial in Slovenia, Estonia, Belgium and others.

Randomised
Yes
Comparator
Placebo is identical to IMP but with no active substance (placebo-controlled).
Target Sample Size
92
Trial Duration For Participant
532

Eligibility

Recruits 92 No vulnerable populations selected (isVulnerablePopulationSelected: false). Participants must be ≥18 years and provide informed consent (ICF). No assent procedures for minors are applicable..

Pregnancy Exclusion
Are breastfeeding or pregnant as determined by a positive serum pregnancy test at the Screening Visit or urine human chorionic gonadotropin test at the Baseline Visit (Day 1).
Vulnerable Population
No vulnerable populations selected (isVulnerablePopulationSelected: false). Participants must be ≥18 years and provide informed consent (ICF). No assent procedures for minors are applicable.

Inclusion criteria

  • {"criterion_text":"- Are ≥ 18 years of age at the time of signing the informed consent form (ICF)."}
  • {"criterion_text":"- Have met clinical diagnostic criteria for typical CIDP or one of the following CIDP variants: multifocal CIDP or motor CIDP per the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) Guideline on Diagnosis and Treatment of CIDP."}
  • {"criterion_text":"- Have electrodiagnostic test results supporting the diagnosis of CIDP per the EAN/PNS guideline on diagnosis and treatment of CIDP."}
  • {"criterion_text":"- Are currently on, and have been receiving, chronic, stable doses of systemic corticosteroids (i.e., daily or every other day oral or pulse regimen), or immunoglobulin therapy (intravenous immunoglobulin [IVIg] or subcutaneous immunoglobulin [SCIg]) ± low dose oral corticosteroids, for at least 3 months for the treatment of CIDP at the time of the Screening Visit."}

Exclusion criteria

  • {"criterion_text":"- Have current or prior history of IgM paraproteinemia with or without antimyelin-associated-glycoprotein antibodies."}
  • {"criterion_text":"- Have distal, sensory, or focal CIDP, or have a diagnosis of autoimmune nodopathy per the EAN/PNS guideline on diagnosis and treatment of CIDP."}
  • {"criterion_text":"- Have polyneuropathy with etiology other than CIDP including but not limited to: • Multifocal motor neuropathy • Hereditary demyelinating neuropathy • Polyneuropathy, organomegaly, endocrinopathy, or monoclonal protein and skin change syndromes • Lumbosacral radiculoplexus neuropathy • Systemic illnesses, including vitamin deficiency syndromes and paraneoplastic neuropathies • Drug- or toxin-induced"}
  • {"criterion_text":"- Have diabetes mellitus (DM) and meets any of the following criteria: • Does not have both typical CIDP and strong evidence of demyelination on nerve conduction study. • In the opinion of the Investigator, there is evidence of poorly controlled DM immediately preceding the diagnosis of CIDP. • In the opinion of the Investigator, there is evidence of poorly controlled DM at Screening."}
  • {"criterion_text":"- Have a history of myelopathy or evidence of central demyelination."}
  • {"criterion_text":"- Are breastfeeding or pregnant as determined by a positive serum pregnancy test at the Screening Visit or urine human chorionic gonadotropin test at the Baseline Visit (Day 1)."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- The proportion of participants remaining Relapse-free by Week 24.","definition_or_measurement_approach":"Relapse-free status by Week 24 assessed by aINCAT score (main objective: preventing Relapse as assessed by aINCAT)."}

Secondary endpoints

  • {"endpoint_text":"- Change from baseline to Week 24 in I-RODS.","definition_or_measurement_approach":"Change from baseline to Week 24 measured by I-RODS instrument."}
  • {"endpoint_text":"- Change from baseline to Week 24 in Mean Grip Strength in the dominant hand.","definition_or_measurement_approach":"Change from baseline to Week 24 in mean grip strength of dominant hand (measurement using vigorimeter / grip strength device)."}
  • {"endpoint_text":"- Change from baseline to Week 24 in MRC-SS.","definition_or_measurement_approach":"Change from baseline to Week 24 measured by MRC sum score (MRC-SS)."}
  • {"endpoint_text":"- Change from baseline to Week 24 in aINCAT score.","definition_or_measurement_approach":"Change from baseline to Week 24 measured by adjusted INCAT (aINCAT) score."}

Recruitment

Registry Or Advocacy Recruitment
True, Advocacy Group (no specific advocacy organisation name provided in documents; multiple 'Advocacy Group' recruitment materials referenced).
Digital Remote Recruitment
True, digital/remote methods include banner ads, social media posts, web postings, and advocacy group email/newsletter materials (country-specific versions referenced).
Planned Sample Size
92
Recruitment Window Months
55
Consent Approach
Consent provided by the participant (participants must be ≥18 years). Informed Consent Forms (L1_SIS and ICF_Main and related ICF documents) are provided; multiple language versions available (examples in files: EN, DE, FR, NL, IT, ES, HU, PL, PT, RO, SI, SK, BG, GR, EE, FI, NO, IE). No assent for minors (minors excluded). Specific pregnancy-related consent/information materials are also provided where applicable.

Methods

  • Advocacy group channels (banner ads, emails, newsletter text, web postings) — country-specific versions provided (e.g., files labelled with country codes such as SI, EE, BE, RO, HU, IT, etc.).
  • Printed materials: Brochure, Flyer, Poster — country-specific language versions.
  • Digital channels: Social media and web posts — country-specific versions.
  • Healthcare professional outreach: 'Dr to Patient' letters aimed at clinicians to refer patients.
  • Site-based recruitment materials: Patient visit guides and posters/flyers distributed at sites.
  • Multimedia: Injection training videos and instructions for use.
  • Home Health / Site support: Home Health Care services listed among third parties (e.g., Illingworth Research Group Limited indicated for Home Health Care).
  • Patient reimbursement/travel support (Greenphire listed for patient reimbursement / travel).

Geography

Total Number Of Sites
66
Total Number Of Participants
79

Slovenia

Earliest CTIS Part Ii Submission Date
01-10-2025
Latest Decision Or Authorization Date
29-10-2025
Processing Time Days
28
Number Of Sites
1
Number Of Participants
3

Sites

Site Name
University Medical Center Ljubljana
Department Name
Institute of Clinical Neurophysiology
Contact Person Name
Blaz Koritnik
Contact Person Email
blaz.koritnik@kclj.si

Estonia

Earliest CTIS Part Ii Submission Date
15-10-2025
Latest Decision Or Authorization Date
31-10-2025
Processing Time Days
16
Number Of Sites
1
Number Of Participants
3

Sites

Site Name
Clinic4U OÜ
Contact Person Name
Katrin Gross-Paju

Belgium

Earliest CTIS Part Ii Submission Date
10-10-2025
Latest Decision Or Authorization Date
13-11-2025
Processing Time Days
34
Number Of Sites
1
Number Of Participants
5

Sites

Site Name
UZ Leuven
Department Name
Neurology
Contact Person Name
Kristl Claeys
Contact Person Email
kristl.claeys@uzleuven.be

Romania

Earliest CTIS Part Ii Submission Date
02-10-2025
Latest Decision Or Authorization Date
13-11-2025
Processing Time Days
42
Number Of Sites
2
Number Of Participants
2

Sites

Site Name
Institutul Clinic Fundeni
Department Name
Neurologie I
Contact Person Name
Adriana Dulamea
Contact Person Email
adrianadulamea@gmail.com
Site Name
Brainaxy Clinic S.R.L.
Department Name
Spitalizare de zi
Contact Person Name
Any Axelerad
Contact Person Email
docuaxi@yahoo.com

Hungary

Earliest CTIS Part Ii Submission Date
14-10-2025
Latest Decision Or Authorization Date
29-10-2025
Processing Time Days
15
Number Of Sites
3
Number Of Participants
5

Sites

Site Name
Kistarcsai Flor Ferenc Korhaz
Department Name
Neurológia és Stroke Osztály
Contact Person Name
Gyula Panczel
Contact Person Email
panczel.gyula@florhosp.hu
Site Name
Clinexpert Kft.
Contact Person Name
Ferenc Fazekas
Contact Person Email
dr.f.fazekas@gmail.com
Site Name
University Of Pecs
Department Name
Klinikai Központ, Neurológiai Klinika
Contact Person Name
Endre Pál
Contact Person Email
pal.endre@pte.hu

Italy

Earliest CTIS Part Ii Submission Date
13-10-2025
Latest Decision Or Authorization Date
28-10-2025
Processing Time Days
15
Number Of Sites
11
Number Of Participants
8

Sites

Site Name
Azienda Ospedaliero Universitaria Pisana
Department Name
UO Neurologia
Contact Person Name
Gabrielle Siciliano
Site Name
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Department Name
UOC Neurologia
Contact Person Name
Marco Luigetti
Site Name
Azienda Ospedaliero-Universitaria Policlinico Umberto I
Department Name
Human Neuroscience Health
Contact Person Name
Maurizio Inghilleri
Site Name
Fondazione Istituto Neurologico Nazionale Casimiro Mondino
Department Name
UO Neuroncologia
Contact Person Name
Elisa Vegezzi
Contact Person Email
elisa.vegezzi@mondino.it
Site Name
IRCCS Foundation Istituto Neurologico Carlo Besta
Department Name
SC Neurologia 3 - Neuralgologia
Contact Person Name
Eleonora Dalla Bella
Site Name
Azienda Unita Sanitaria Locale Di Bologna
Department Name
UOC Clinical Neurologica
Contact Person Name
Vincenzo Angelo Donadio
Contact Person Email
vincenzo.donadio@unibo.it
Site Name
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii
Department Name
Neurologia
Contact Person Name
Barbara Frigeni
Contact Person Email
bfrigeni@asst-pg23.it
Site Name
Centro Clinico Nemo
Department Name
Centro Clinico Nemo - Brescia
Contact Person Name
Massimiliano Filosto
Contact Person Email
massimiliano.filosto@unibs.it
Site Name
Azienda Ospedaliero-Universitaria Senese
Department Name
UOC Neurologia
Contact Person Name
Federica Ginanneschi
Contact Person Email
federica.ginanneschi@unisi.it
Site Name
Ospedale San Raffaele S.r.l.
Department Name
UO Neurologia
Contact Person Name
Stefano Previtali
Contact Person Email
previtali.stefano@hsr.it
Site Name
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Department Name
SSD Malattie Neuromuscolari Rare
Contact Person Name
Francesca Magri

Austria

Earliest CTIS Part Ii Submission Date
14-10-2025
Latest Decision Or Authorization Date
03-11-2025
Processing Time Days
20
Number Of Sites
1
Number Of Participants
3

Sites

Site Name
Medical University Of Vienna
Department Name
Department of Neurology
Contact Person Name
Jakob Rath
Contact Person Email
jakob.rath@meduniwien.ac.at

Bulgaria

Earliest CTIS Part Ii Submission Date
13-10-2025
Latest Decision Or Authorization Date
03-11-2025
Processing Time Days
21
Number Of Sites
5
Number Of Participants
10

Sites

Site Name
Multiprofile Hospital For Active Treatment In Neurology And Psychiatry St. Naum EAD
Department Name
Clinic of Neurodegenerative and Peripheral Nerve Disorders
Contact Person Name
Ivan Milanov
Contact Person Email
ubalnp@yahoo.com
Site Name
Medical Center Academica 2008 EOOD
Contact Person Name
Plamen Tsvetanov
Contact Person Email
tzvetanovmd@mail.bg
Site Name
University Multiprofile Hospital For Active Treatment And Emergency Medicine N I Pirogov
Department Name
Clinic of neurological diseases
Contact Person Name
Mariya Dimitrova
Contact Person Email
dr.m.i.dimitrova@gmail.com
Site Name
Diagnostics And Consultation Center Convex Ltd.
Contact Person Name
Sashka Zhelyazkova
Contact Person Email
doc_sashka@abv.bg
Site Name
Military Medical Academy
Department Name
Clinic of neurological diseases
Contact Person Name
Vanya Deneva
Contact Person Email
vania_den@yahoo.com

Germany

Earliest CTIS Part Ii Submission Date
01-08-2025
Latest Decision Or Authorization Date
29-10-2025
Processing Time Days
88
Number Of Sites
4
Number Of Participants
7

Sites

Site Name
Charite Research Organisation GmbH
Department Name
NeuroCure Clinical Research Center – NCRC Klinik fur Neurologie
Contact Person Name
Frauke Stascheit
Contact Person Email
frauke.stascheit@charite.de
Site Name
Katholisches Klinikum Bochum gGmbH
Department Name
Neurologische Universitätsklink - St. Josef Hospital
Contact Person Name
Kalliopi Pitarokoili
Contact Person Email
kalliopi.pitarokoili@rub.de
Site Name
Universitaetsklinikum Ulm AöR
Department Name
Klinik für Neurologie
Contact Person Name
Johannes Dorst
Contact Person Email
johannes.dorst@uni-ulm.de
Site Name
Klinikum Wuerzburg Mitte gGmbH
Department Name
Klinik für Neurologie und Neurologische Frührehabilitation
Contact Person Name
Mathias Maürer

Denmark

Earliest CTIS Part Ii Submission Date
10-10-2025
Latest Decision Or Authorization Date
28-10-2025
Processing Time Days
18
Number Of Sites
2
Number Of Participants
4

Sites

Site Name
Rigshospitalet
Department Name
Department of neurology
Contact Person Name
Tina Dysgaard
Contact Person Email
tina.dysgaard@regionh.dk
Site Name
Odense University Hospital
Department Name
Department of neurology
Contact Person Name
Soren Sindrup
Contact Person Email
soeren.sindrup@rsyd.dk

Spain

Earliest CTIS Part Ii Submission Date
16-10-2025
Latest Decision Or Authorization Date
31-10-2025
Processing Time Days
15
Number Of Sites
7
Number Of Participants
4

Sites

Site Name
Hospital Universitario Reina Sofia
Department Name
Neurology
Contact Person Name
Eduardo Agüera Morales
Contact Person Email
neuroensayos@gmail.com
Site Name
Hospital Universitari Vall D Hebron
Department Name
Neurology
Contact Person Name
Raùl Juntas Morales
Contact Person Email
raul.juntas@vallhebron.cat
Site Name
Hospital Universitario Y Politecnico La Fe
Department Name
Neurology
Contact Person Name
María Teresa Sevilla Mantecón
Contact Person Email
sevilla_ter@gva.es
Site Name
Hospital De La Santa Creu I Sant Pau
Department Name
Neuroloy
Contact Person Name
Luis Antonio Querol Gutiérrez
Contact Person Email
lquerol@santpau.cat
Site Name
Hospital Universitario Basurto
Department Name
Neurology
Contact Person Name
Solange Kapetanovic Garcia
Site Name
Complexo Hospitalario Universitario De Santiago
Department Name
Neurology
Contact Person Name
Tania Garcia Sobrino
Contact Person Email
tania.garcia.sobrino@sergas.es
Site Name
Hospital Universitario Y Politecnico La Fe - (additional site entry in list)
Department Name
Neurology

Finland

Earliest CTIS Part Ii Submission Date
30-09-2025
Latest Decision Or Authorization Date
29-10-2025
Processing Time Days
29
Number Of Sites
1
Number Of Participants
1

Sites

Site Name
Turku University Hospital
Department Name
Neurology
Contact Person Name
Manu Turku
Contact Person Email
manu.jokela@tyks.fi

Greece

Earliest CTIS Part Ii Submission Date
26-09-2025
Latest Decision Or Authorization Date
30-10-2025
Processing Time Days
34
Number Of Sites
7
Number Of Participants
4

Sites

Site Name
Eginitio Hospital
Department Name
1st Neurology Department
Contact Person Name
Leonidas Stefanis
Contact Person Email
lstefanis@bioacademy.gr
Site Name
University General Hospital Of Ioannina
Department Name
Neurology clinic
Contact Person Name
Spyridon Konitsiotis
Contact Person Email
skonitso@gmail.com
Site Name
University General Hospital Of Heraklion
Department Name
Neurology Department
Contact Person Name
Panayiotis Mitsias
Contact Person Email
p.mitsias@gmail.com
Site Name
University General Hospital Of Alexandroupoli
Department Name
University Department of Neurology
Contact Person Name
Aikaterini Terzoudi
Contact Person Email
katerzoudi@hotmail.com
Site Name
General University Hospital Of Patras
Department Name
Neurology Department, Neuromuscular Unit
Contact Person Name
Elisabeth Chroni
Contact Person Email
echroni@yahoo.com
Site Name
University General Hospital Attikon
Department Name
Second Department of Neurology - National and Kapodistrian University of Athens
Contact Person Name
Georgios Tsivgoulis
Contact Person Email
tsivgoulisgiorg@yahoo.gr
Site Name
General University Hospital Of Larissa
Department Name
Neurology Department
Contact Person Name
Efthimios Dardiotis
Contact Person Email
ebsdar@gmail.com

Netherlands

Earliest CTIS Part Ii Submission Date
10-10-2025
Latest Decision Or Authorization Date
03-11-2025
Processing Time Days
24
Number Of Sites
1
Number Of Participants
1

Sites

Site Name
Universitair Medisch Centrum Utrecht
Department Name
Neurology
Contact Person Name
Ludo Van der Pol
Contact Person Email
w.l.vanderpol@umcutrecht.nl

Portugal

Earliest CTIS Part Ii Submission Date
29-08-2025
Latest Decision Or Authorization Date
28-10-2025
Processing Time Days
60
Number Of Sites
3
Number Of Participants
5

Sites

Site Name
Unidade Local De Saude De Matosinhos E.P.E.
Department Name
Serviço de Neurologia
Contact Person Name
Sandra Moreira
Site Name
Unidade Local De Saude De Gaia/Espinho E.P.E.
Department Name
Serviço de Neurologia
Contact Person Name
Henrique Moniz Costa
Site Name
Unidade Local De Saude De Almada-Seixal E.P.E.
Department Name
Serviço de Neurologia
Contact Person Name
Pedro Pereira

Poland

Earliest CTIS Part Ii Submission Date
16-10-2025
Latest Decision Or Authorization Date
31-10-2025
Processing Time Days
15
Number Of Sites
11
Number Of Participants
5

Sites

Site Name
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie
Department Name
Oddzial Kliniczny Neurologii
Contact Person Name
Agnieszka Slowik
Contact Person Email
neurologiabk@su.krakow.pl
Site Name
Krakowski Szpital Specjalistyczny Im. Sw. Jana Pawla II
Department Name
Oddział Neurologiczny z Pododdziałem Udarowym i z Pododdziałem Rehabilitacji Neurologicznej
Contact Person Name
Agnieszka Kulaga
Contact Person Email
kulaga_a@poczta.onet.pl
Site Name
Clinical Research Center Sp. z o.o. Medic-R sp.k.
Department Name
Neurology
Contact Person Name
Artur Druzdz
Contact Person Email
artur.druzdz@cr-center.pl
Site Name
Neurologia Śląska Centrum Medyczne
Contact Person Name
Marek Smilowski
Contact Person Email
marek.smilowski2@gmail.com
Site Name
Medicover Integrated Clinical Services Sp. z o.o.
Department Name
MICS Centrum Medyczne Bydgoszcz
Contact Person Name
Lukasz Rzepinski
Contact Person Email
luk.rzepinski@gmail.com
Site Name
Centrum Medyczne Hope Clinic
Department Name
Neurology
Contact Person Name
Sebastian Szklener
Contact Person Email
sebastianszklener@gmail.com
Site Name
Clinirem Sp. z o.o. (Bydgoszcz)
Contact Person Name
Urszula Chyrchel-Paszkiewicz
Contact Person Email
pgluchyrchel@gmail.com
Site Name
Uniwersyteckie Centrum Kliniczne
Contact Person Name
Mariusz Kwarciany
Contact Person Email
mariusz.kwarciany@gumed.edu.pl
Site Name
Clinirem Sp. z o.o. (Wielicka 42)
Contact Person Name
Urszula Chyrchel-Paszkiewicz
Contact Person Email
pgluchyrchel@gmail.com
Site Name
Medicover Integrated Clinical Services Sp. z o.o. (Bydgoszcz secondary)
Contact Person Name
Lukasz Rzepinski
Contact Person Email
luk.rzepinski@gmail.com
Site Name
Additional Polish investigational site (listed)
Department Name
Pending / N/A
Contact Person Name
Pending
Contact Person Email
Pending@pending

Slovakia

Earliest CTIS Part Ii Submission Date
26-09-2025
Latest Decision Or Authorization Date
29-10-2025
Processing Time Days
33
Number Of Sites
3
Number Of Participants
4

Sites

Site Name
Univerzitna Nemocnica Martin
Department Name
Neurologická klinika
Contact Person Name
Monika Turcanova Koprusakova
Contact Person Email
koprusakova@gmail.com
Site Name
Penta Hospitals SK a.s.
Department Name
Neurologické oddelenie
Contact Person Name
Erika Zacharova
Site Name
Fakultna Nemocnica S Poliklinikou J. A. Reimana Presov
Department Name
Neurologické oddelenie
Contact Person Name
Anna Cvengrošová
Contact Person Email
annacvengrosova@gmail.com

Norway

Earliest CTIS Part Ii Submission Date
13-10-2025
Latest Decision Or Authorization Date
03-11-2025
Processing Time Days
21
Number Of Sites
1
Number Of Participants
3

Sites

Site Name
Oslo University Hospital HF
Department Name
Division of Clinical Neuroscience
Contact Person Name
Angelina Maniaol
Contact Person Email
angman@ous-hf.no

Ireland

Earliest CTIS Part Ii Submission Date
09-10-2025
Latest Decision Or Authorization Date
31-10-2025
Processing Time Days
22
Number Of Sites
1
Number Of Participants
2

Sites

Site Name
University Hospital Waterford
Department Name
Neurology
Contact Person Name
Orla Tuohy
Contact Person Email
orla.tuohy@hse.ie

Sponsor

Primary sponsor

Full Name
Immunovant Sciences GmbH
Organisation Type
Pharmaceutical company
Country Of Registered Address
Switzerland

Contract research organisations

Name
PPD Global Ltd.
Responsibilities
Multiple operational roles (codes listed for clinical operations, monitoring, lab, etc.); contact: pprovalsgr.sm@thermofisher.com
Name
Syneos Health Inc.
Responsibilities
IDMC and other clinical operations support; contact: donna.davison@syneoshealth.com
Name
Marken LLP
Responsibilities
Logistics / distribution support (roles indicated by sponsor duties)
Name
Medidata Solutions Inc.
Responsibilities
eClinical platform / data capture (codes present)
Name
Suvoda LLC
Responsibilities
eTMF / eClinical systems (codes present)
Name
Longboat Clinical Limited
Responsibilities
Site technology solutions; prescreening logs and site training

Third parties

  • {"country":"Netherlands","full_name":"CliniChain B.V.","duties_or_roles":"Equipment: Vigorimeters","organisation_type":"Pharmaceutical company"}
  • {"country":"United Kingdom","full_name":"Catalent Cts (Edinburgh) Limited","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
  • {"country":"Greece","full_name":"PPD Global Ltd.","duties_or_roles":"Duties codes listed (multiple responsibilities); explicit value fields: none","organisation_type":"Pharmaceutical company"}
  • {"country":"United Kingdom","full_name":"Illingworth Research Group Limited","duties_or_roles":"Home Health Care","organisation_type":"Hospital/Clinic/Other health care facility"}
  • {"country":"United States","full_name":"Greenphire LLC","duties_or_roles":"Patient reimbursement / Travel","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"France","full_name":"Quipment","duties_or_roles":"Medical and study equipment","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"Netherlands","full_name":"Emsere B.V.","duties_or_roles":"Laboratory equipment","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Eclinical Solutions LLC","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
  • {"country":"United Kingdom","full_name":"PPD Global Limited","duties_or_roles":"Multiple roles (codes present); explicit value fields: none","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Cogstate Inc.","duties_or_roles":"Rater training","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Medidata Solutions Inc.","duties_or_roles":"","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"United States","full_name":"Suvoda LLC","duties_or_roles":"","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"United States","full_name":"Primevigilance USA Inc.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
  • {"country":"France","full_name":"Voisin Consulting Life Sciences","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Syneos Health Inc.","duties_or_roles":"IDMC","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Yprime LLC","duties_or_roles":"eCOA / ePRO","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"United States","full_name":"Eresearchtechnology Inc.","duties_or_roles":"Central ECG","organisation_type":"Pharmaceutical company"}
  • {"country":"United Kingdom","full_name":"PPD Global Limited (Granta Park, Great Abington)","duties_or_roles":"Multiple roles including central trial activities (codes listed)","organisation_type":"Pharmaceutical company"}
  • {"country":"United Kingdom","full_name":"Innovative Trials Limited","duties_or_roles":"Patient recruitment","organisation_type":"Pharmaceutical company"}
  • {"country":"Ireland","full_name":"Longboat Clinical Limited","duties_or_roles":"Site Technology Solutions: Prescreening logs, Visit planning tool, Site training","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"Belgium","full_name":"MEDPACE LABORATORIES","duties_or_roles":"Central Lab","organisation_type":"Laboratory/Research/Testing facility"}
  • {"country":"Canada","full_name":"Syneos Health Clinique Inc.","duties_or_roles":"","organisation_type":"Hospital/Clinic/Other health care facility"}
  • {"country":"","full_name":"Additional third parties listed (various)","duties_or_roles":"","organisation_type":""}

Investigational products

Investigational Product Name
IMVT-1402
Active Substance
IMEROPRUBART
Modality
Monoclonal antibody
Routes Of Administration
Subcutaneous
Route
Subcutaneous
Maximum Dose
600 mg (max daily dose amount as listed)
Investigational Product Name
Placebo is identical to IMP but with no active substance.
Modality
Other
Combination Treatment
Yes

Related trials

Other published trials that may interest you.